Amedisys (AMED): Revenue Not OpEx Tells The Story - Jefferies

October 31, 2016 9:03 AM EDT
Get Alerts AMED Hot Sheet
Price: $38.86 +0.44%

Rating Summary:
    5 Buy, 9 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 16 | Down: 26 | New: 28
Trade AMED Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst, Brian Tanquilut, reiterated his Buy rating on shares of Amedisys (NASDAQ: AMED) but cut his price target to $50 from $59 after a pre-release of weak Q3 EPS.

While pressuring earnings growth and price targets, the misstep seems mostly attributable to disruptions related to the rollout of its new IT system. While the EPS miss is disappointing, reported revenues were actually above consensus, highlighting strength in hospice and personal care. Beyond Q3, the analyst believes the company remains positioned to see healthy organic volume growth and margin expansion once its HCHB rollout is completed at year-end, which sets the stock up for good EPS growth going forward.

For an analyst ratings summary and ratings history on Amedisys click here. For more ratings news on Amedisys click here.

Shares of Amedisys closed at $42.55 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Jefferies & Co, Earnings

Add Your Comment